Specifically, R-2HG inhibited FTO activity, thereby increasing global m6A RNA modification and reducing the stability of MYC/CEBPA transcripts in R-2HG-sensitive leukemia cells, showing antitumor activity. The gene discussed is MYC; the disease is leukemia.